Your partner for accessible multiplex biomarker testing solutions
Contact Us
Analyzing multiple analytes per well supports deeper biololgical insights from a single sample while targeted panels reduce complexity and operating expenses.
Providing researchers, diagnostics manufacturers, clinical labs, and vet clinics a streamlined and cost-effective multiplex proteomics platform that delivers multiple biomarker insights simultaneously across diverse sample types, offering a more flexible and efficient alternative to singleplex assays and large-scale proteomics solutions.
Enables the development of affordable and efficient biomarker testing solutions by combining easy-to-use multiplexing technology with AI-driven analysis into a single workflow for multiple sample types to power the translation of research discoveries into clinical impact
Price
Pictor removes cost barriers in diagnostics with a low-cost PictImager™ platform, a depot service model, and affordable per-sample pricing regardless of batch size.
By using standard detection reagents, it keeps consumable costs low while making advanced testing accessible for labs in
both established and emerging markets.
Performance
Designed for high-throughput testing, Pictor delivers results in under 1 minute for 96 samples with a quick turnaround time (TAT)
and an intuitive workflow.
AI-powered Pictorial™ analysis software automates data processing, seamlessly integrating with LIMS for streamlined reporting. Its compact design makes it ideal for mobile labs, vet trucks, and decentralized facilities, ensuring efficiency in any setting.
Productivity
Pictor offers true scalability with multiplexing for up to 50 analytes per test, supporting batch flexibility—run an entire plate or just one column as needed.
It works with multiple sample types (blood, saliva, plasma, milk) without reconfiguration and provides off-the-shelf ready panels
for human and animal health. For specialized needs, labs can easily customize panels for disease-specific testing, making Pictor a highly adaptable solution.
Join us in our mission to revolutionize proteomics and to empower better management of complex diseases through creating more insights from a single test
Pictor has been collaborating with partners around the globe.
Jamie brings over 20 years of transformative leadership in genomics and molecular diagnostics. She has successfully led the development, validation, and commercialization of more than 40 complex molecular tests across global markets. Jamie previously served as COO at PGDx and Inivata, where she played a pivotal role in launching cutting-edge biopsy products and achieving two M&A exits. She is also the founder of BRIDGenomics, a consulting firm supporting diagnostics innovation. A strategic operator and scientist, Jamie integrates Six Sigma methodologies with deep technical expertise to drive product innovation and operational excellence. She holds multiple patents, is a recognized industry speaker, and serves on the board of DxTerity and bioAffinity Technologies (Nasdaq: BIAF; BIAFW). Jamie earned her Ph.D. in Molecular & Cellular Biology from Oregon State University and completed her postdoctoral studies at UC Berkeley. She is passionate about delivering impactful, science-driven solutions to the clinical diagnostics market.
Kate is a seasoned biotech leader with 25 years of experience in technology and product development, specializing in molecular diagnostics, oncology, and next-generation sequencing. She has successfully led cross-functional teams in developing and validating innovative commercial products for cancer screening, companion diagnostics, NIPT, and pharmacogenomics. Kate is highly skilled in optimizing end-to-end processes within regulated environments, ensuring compliance with FDA, CLIA, CAP, IVDR, and ISO standards. Her leadership has been instrumental in the development of groundbreaking technologies, including the Galleri™ Multi-Cancer Early Detection Test and Oncomine™ Dx. Previously, she held key roles at GRAIL, ThermoFisher, and Agena Bioscience, driving innovation and market success. With a Ph.D. from UCSD and a B.S. from the University of Michigan, Kate combines scientific expertise with operational excellence to advance cutting-edge diagnostic solutions.
Yoichi is an experienced immunologist with over 15 years of expertise in vaccine research and immune response. He previously served as a faculty member at Albany Medical College and led NIH-funded studies focused on pre-clinical vaccine development. His early work on a universal influenza vaccine contributed to the launch of a biotech startup in Australia. Yoichi holds a Ph.D. in Medical Sciences from the Australian National University and has secured grants from leading organizations including the NIH and American Lung Association. He also brings experience as a scientific reviewer and editor for top-tier medical journals.
A seasoned commercial leader with deep expertise in clinical and proteomics, Janine consistently delivers financial growth and strategic value across diagnostics and life sciences. She leads commercial expansion into key global markets and builds customer success teams that enhance both investor confidence and strategic valuation. Her experience spans the full product lifecycle, from research-use-only to IVD. A pioneer in the early clinical adoption of next-generation sequencing, she drives its integration into oncology decision support. Janine brings sharp market insight, a results-driven approach, and a strong commitment to equity, sustainability, and advancing women in STEM.
Claire Zimmerman is a strategic, results-driven leader with a strong track record in business operations, governance, and HR management. As Director of Business Operations at Pictor, she drives organizational effectiveness, resource optimization, and alignment with strategic goals. Since joining Pictor, Claire has led initiatives that streamlined processes, enhanced governance, and fostered a collaborative culture—positioning the company for sustainable growth in the biotech and diagnostics space. With deep expertise in cross-functional leadership, change management, and compliance, Claire is known for delivering measurable improvements in efficiency and performance. She builds high-performing teams, cultivates strong stakeholder relationships, and implements strategic solutions that strengthen operations and support Pictor’s mission to advance innovative diagnostics.
With extensive Board and executive leadership experience across diagnostics, biotech, and life sciences, Paul Kinnon has led transformative growth in both public and private companies. Most recently, CEO of Diadem, he advanced the development and commercialization of a breakthrough blood test for early Alzheimer’s detection. His leadership roles at PredicImmune, Transgenomic Inc., Thermo Fisher (Life Technologies), Guava Technologies, Cellomics, and ZyGEM highlight a strong track record in capital fundraising, M&A, commercial scaling, and platform innovation. Paul has successfully launched disruptive technologies across oncology, clinical diagnostics, and discovery, often transforming early-stage ventures into commercially competitive enterprises. His strategic insight, global network, and operational discipline make him a key asset in guiding Pictor’s growth and delivering value through science-driven innovation.
Jamie is CEO of Pictor Diagnostics with 20 years of proven leadership in genomics and molecular diagnostics. She has guided teams in developing and commercializing 40+ high-complexity tests (LDTs and IVDs) globally. As COO at PGDx (acquired by LabCorp) and Inivata (acquired by NeoGenomics), she led the launch of liquid biopsy products, and two M&A exits totaling ~$1B in 2021. At Inivata, she raised $25M in capital and led the company from R&D to early commercialization, launching two products with a market value of $8.64B. At Quest Diagnostics, she pioneered NGS clinical assays and product lines. Jamie is also founder and CEO of BRIDGenomics, and serves on the boards of bioAffinity [NASDAQ:BIAF] and DxTerity. She holds multiple patents, has authored peer-reviewed publications, and is a recognized thought leader. Jamie earned her Ph.D. from Oregon State University and completed postdoctoral training at UC Berkeley.
Bringing over 30 years of leadership experience across the infrastructure and technology sectors, Marko has built a career spanning finance, operations, and sales in New Zealand, Australia, and the United States. As former CEO of Infratil Limited and infrastructure investment manager H.R.L. Morrison & Co., he led a period of exceptional growth from 2008 through 2021, expanding funds under management from $2.1B to $25B and delivering significant shareholder value. His strategic leadership is marked by a consistent ability to scale companies and drive strong returns. As co-founder and General Partner of Maker Partners and MQB Partners, he is active in consumer venture capital and early-stage innovation in the health sector and med-tech. Marko has held a number of listed and private company governance roles and is a Fellow of the NZ Institute of Chartered Accountants. He holds a BCA from Victoria University and an MBA from Harvard Business School. He currently serves as Operating Partner at Morrison & Co and holds board positions with One New Zealand, Amplitel, Tend, No Issue, and Abel Fragrance.
On the Diagnosing Dx podcast, Pictor Chief Commercial Officer Janine McMurdie—drawing on leadership roles at Amgen and Ion Torrent—explores why proteomics is emerging as the next wave in diagnostics. She details how Pictor’s fast, flexible, and affordable platform puts patients first, navigates an evolving regulatory landscape, and leverages optimism to accelerate a science‑led future of precision health. Tune in on YouTube, Spotify, or Apple Podcasts to hear the full conversation.
Learn More
In David Meltzer’s recent LinkedIn Live session (watch from 13:42), CEO Jamie Platt contrasts genomics with proteomics, explains why real‑time protein insights are the next frontier in precision health, and reflects on a career of billion‑dollar exits and purpose‑built teams—reinforcing Pictor’s momentum to deliver transformative global diagnostics.
Learn More
The July issue of the Carlsbad Business Journal features Pictor’s Carlsbad lab opening on its front page, spotlighting a pivotal milestone in our U.S. expansion and drive to advance proteomics‑powered diagnostics. The coverage, made possible through the support of the Carlsbad Chamber of Commerce, underscores our commitment to grow alongside the region’s vibrant life‑sciences community.
Learn More
Pictor celebrates senior leader Kate Rhodes’s inclusion in the Carlsbad Chamber of Commerce’s “50 Over 50 – Special Edition,” which honors professionals who continue to shape industry and community. The recognition highlights Kate’s decades‑long leadership, operational excellence, and lasting impact on both Pictor’s growth and the broader San Diego life‑sciences ecosystem.
Learn More
On the June 3, 2025 episode of Tacos & Tech, host Neal Bloom speaks with Pictor CEO Jamie Gibson about how real‑time protein diagnostics are changing healthcare. The conversation covers the shift from DNA‑based tests to fast, accessible proteomics, Pictor’s move to San Diego, and the leadership lessons driving the company’s mission to make diagnostics quicker, cheaper, and more personal.
Learn More
The San Diego Business Journal spotlighted Pictor’s non-invasive, saliva-based proteomics technology—capable of delivering results in just four hours. CEO Jamie Platt discussed securing $5M in seed funding, plans to raise a $30M Series A, and a partnership-driven revenue model aimed at accelerating affordable, high-throughput testing for both pharma and clinical labs across the United States.
Learn More
Clinical Lab Products featured Pictor’s establishment of its U.S. headquarters in San Diego, noting this pivotal move to scale operations across North America. The coverage underscores our accelerating growth strategy and invites industry partners and investors to join upcoming ribbon‑cutting and executive sessions as we advance accessible proteomics solutions.
Learn More
Yahoo Finance covered our new Carlsbad headquarters, $5 M seed funding, and plans to scale low‑cost, high‑throughput multiplex proteomics testing—capitalizing on a recent court decision that keeps lab‑developed tests under CLIA oversight and clears the path for rapid U.S. expansion.
Learn More
GenomeWeb, a leading genomics and diagnostics publication, covered Pictor’s move to establish its U.S. headquarters and close a $5 M seed round. The feature introduces our accessible proteomics platform to more than 100,000 life‑science professionals and signals the start of our next fundraising phase.
Learn More
Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to delivering cutting-edge diagnostic capabilities to clinical laboratories worldwide.
Learn MoreGet in touch with us to discuss partnerships, investment opportunities, or learn more about our platform.
For support, requests or inquiries info@PictorDx.com
